Rúbia Darc Machado

Dr. Rúbia Darc Machado

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2022 in Molecules
Verified
Journal Article
Open access
PDF file
RMRúbia Darc Machado
Rúbia Darc Machado
JSJúlio C. G. Silva
Júlio C. G. Silva
LSLuís Antônio Dantas Silva
Luís Antônio Dantas Silva
GOGerlon de Almeida Ribeiro Oliveira
Gerlon de Almeida Ribeiro Oliveira
LLLuciano Lião
Luciano Lião
KRKENNIA REZENDE
KENNIA REZENDE
Psoralen (PSO) and 5-methoxypsoralen (5-MOP) are widely used drugs in oral photochemotherapy against vitiligo and major bioactive components of root bark extract of Brosimum gaudichaudii Trécul (EBGT), previously standardized by LC-MS. However, the exceptionally low water solubility of these psoralens can cause incomplete and variable bioavailability limiting their applications and patient adherence to treatment. Therefore, the purpose of this work was to investigate the effects of 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) inclusion complex on the solubility and jejunal permeability of PSO and 5-MOP from EBGT. Characterization of inclusion complexes were evaluated by current methods in nuclear magnetic resonance studies on aqueous solution, Fourier transform infrared spectroscopy, thermal analysis, and scanning electron microscopy in solid state. Ex vivo rat jejunal permeability was also investigated and compared for both pure psoralens and plant extract formulation over a wide HP-β-CD concentration range (2.5 to 70 mM). Phase solubility studies of the PSO- and 5-MOP-HP-β-CD inclusion complex showed 1:1 inclusion complex formation with small stability constants (Kc < 500 M−1). PSO and 5-MOP permeability rate decreased after adding HP-β-CD by 6- and 4-fold for pure standards and EBGT markers, respectively. Nevertheless, the complexation with HP-β-CD significantly improved solubility of PSO (until 10-fold) and 5-MOP (until 31-fold). As a result, the permeability drop could be overcome by solubility augmentation, implying that the HP-β-CD inclusion complexes with PSO, 5-MOP, or EBGT can be a valuable tool for designing and developing novel oral drug product formulation containing these psoralens for the treatment of vitiligo.

26 June 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
ARAna Cláudia M. Ramos
Ana Cláudia M. Ramos
KRKENNIA REZENDE
KENNIA REZENDE
CTCarolina Marinho Teixeria
Carolina Marinho Teixeria
AFAline R. Fernandes
Aline R. Fernandes
HSHeloa Santos
Heloa Santos
ACAndrea Chaves
Andrea Chaves
The LQFM05 is a prototype drug designed for treatment of psychiatric disorders, such as schizophrenia, exhibiting anxiolytic- and antidepressant-like (12 or 24 µmol/kg) effects in classical behavioral tests. In order to evaluate its pharmacokinetic properties, a liquid chromatography method coupled to a quadrupole time of flight mass spectrometry system (LC-QTOF/MS) was developed and fully validated for LQFM05 analysis in rat plasma and tissue samples (brain, heart, liver, and kidneys). Liquid–liquid extraction, solid phase extraction and protein precipitation were assessed as clean-up procedures for biological samples and analyte enrichment. Plasma and tissue samples underwent protein precipitation as a preliminary step, using acetonitrile. Linearity was fully demonstrated for the dynamic range (10.0 to 900.0 ng/mL), with r2 values higher than 0.99 (RSDslope ≤ 2%, Fcal < Ftab, Ccal < Ctab). Biodistribution studies in rats revealed high brain tissue concentrations (12.4 µg/g), suggesting elevated drug affinity to the main therapeutic target tissue, showing a blood partition coefficient of 1.9. Kidneys also showed great exposure and tissue affinity, suggesting a potential extrahepatic clearance. Likewise, all examined tissues exhibited satisfactory LQFMF05 distribution. The mass fragmentation spectrum indicated the presence of its main metabolite, LQFM235, yielded by high hepatic hydroxylation route, an equally bioactive derivative. Lastly, the developed LC-QTOF/MS method was shown to be sensitive (LOQ = 10 ng/mL), precise and accurate for LQFM05 determination in tissue homogenates and plasma samples.

2 December 2024 in Revista Fitos
Verified
Journal Article
Open access
PDF file
ECEliane Vasconcelos Caixeta
Eliane Vasconcelos Caixeta
DDDanielle Guimarães Almeida Diniz
Danielle Guimarães Almeida Diniz
ITIeda Torres
Ieda Torres
LCLaila Portil Garcino Campos
Laila Portil Garcino Campos
RMRúbia Darc Machado
Rúbia Darc Machado
MBMaria Teresa Freitas Bara
Maria Teresa Freitas Bara
Lafoensia pacari`s leaves have phenolic compounds which may lead to photoprotective and antioxidant properties. The aim of this study was to investigate these activities in the L. pacari phenolics-containing extract (LPE) and to obtain gel cream formulations containing LPE and that have photochemoprotective activity. Phenolic compounds and antioxidant activity were determined. Polyacrylamide & C13-14 Isoparaffin & Laureth-7 (Focus gel® 305) formulation, it added synthetic sunscreen Ethylhexyl methoxycinnamate (Eusolex 2292®) or with both Eusolex 2292® and LPE were prepared. The in vitro sun protection factor (SPF) of these formulations was determined by diffuse reflectance spectroscopy. Preliminary stability of gel creams was evaluated. Total phenols and flavonoids content were 3.31% and 0.315%, respectively. LPE showed antioxidant activity by DPPH, with an EC50 of 5.3 µg. mL-1 and by FRAP methods, in which 1g of the extract reduces 323.62 µM/L of ferrous sulfate. LPE showed an additive effect on the value of SPF when associated with Ethylhexyl methoxycinnamate, an increase of 22% in FPS of the formulation (F3). The data obtained allow us to suggest a trend towards the photoquimoprotective effect of the L. pacari phenolics-containing extract in the studied conditions.